BibTex format

author = {Salas, A and Kant, S and Floyd, L and Kratky, V and Brix, SR and Prendecki, M and Schonermarck, U and Scott, J and Saha, M and Gauckler, P and Li, T and Sharma, PD and Ayoub, I and Morris, AD and Dhaygude, AP and Hruskova, Z and Tesar, V and McAdoo, SP and Little, MA and Derebail, VK and Poulton, CJ and Seo, P and Kronbichler, A and Geetha, D},
doi = {10.1016/j.ekir.2021.08.009},
journal = {Kidney International Reports},
pages = {2903--2907},
title = {ANCA vasculitis induction management during the COVID-19 pandemic},
url = {},
volume = {6},
year = {2021}

RIS format (EndNote, RefMan)

AB - As the severe acute respiratory syndrome coronavirus 2 pandemic evolved and became a global health threat, the safety of immunosuppression in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) became of utmost important for clinicians and patients. Although timely initiation of immunosuppressive therapy is critical to quell the acute inflammation and prevent AAV-associated mortality and morbidity, concerns for increased susceptibility to Coronavirus Disease 2019 (COVID-19), delayed viral clearance, and decreased humoral response to infection led to speculation about modification in induction therapy practices may be deployed by physicians caring for patients with AAV. This international retrospective cohort study investigated the influence of the COVID-19 pandemic on AAV induction therapy and patient outcomes in different parts of the world by studying differences in treatment regimens in the United States, United Kingdom, and Europe.
AU - Salas,A
AU - Kant,S
AU - Floyd,L
AU - Kratky,V
AU - Brix,SR
AU - Prendecki,M
AU - Schonermarck,U
AU - Scott,J
AU - Saha,M
AU - Gauckler,P
AU - Li,T
AU - Sharma,PD
AU - Ayoub,I
AU - Morris,AD
AU - Dhaygude,AP
AU - Hruskova,Z
AU - Tesar,V
AU - McAdoo,SP
AU - Little,MA
AU - Derebail,VK
AU - Poulton,CJ
AU - Seo,P
AU - Kronbichler,A
AU - Geetha,D
DO - 10.1016/j.ekir.2021.08.009
EP - 2907
PY - 2021///
SN - 2468-0249
SP - 2903
TI - ANCA vasculitis induction management during the COVID-19 pandemic
T2 - Kidney International Reports
UR -
UR -
UR -
UR -
VL - 6
ER -